Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes.
UDP-glucuronosyltransferase
cross-correlated selective isoform substrates
human liver microsome
ontogeny
Journal
Journal of clinical pharmacology
ISSN: 1552-4604
Titre abrégé: J Clin Pharmacol
Pays: England
ID NLM: 0366372
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
13
06
2019
accepted:
26
06
2019
entrez:
11
9
2019
pubmed:
11
9
2019
medline:
17
9
2020
Statut:
ppublish
Résumé
An understanding of the postnatal development of hepatic UDP-glucuronosyltransferase (UGT) enzymes is required for accurate prediction of the age-dependent changes in pharmacokinetics of many drugs used in children. However, the maturation rate of hepatic UGT isoforms remains a major knowledge gap. This study aimed to establish the age-associated changes in glucuronidation activity of 10 major hepatic UGT isoforms in humans, namely, UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17. Human liver microsomes from pediatric and adult donors were incubated under optimized incubation conditions to assess the activity rates of hepatic UGT isoforms using a panel of 19 in vitro UGT probe substrates and clinically used drugs. Statistically strong correlations of glucuronidation activities allowed the ontogeny of UGT1A1, UGT1A4, UGT2B7, UGT2B10, and UGT2B15 to be established using multiple selective UGT substrates and matched human liver microsome samples. The postnatal development of hepatic UGTs is isoform-dependent using either individual or cross-correlated selective isoform substrates. Maximal adult activity was reached at different times ranging from within a month (UGT1A1, UGT2B4, UGT2B7, UGT2B10, and UGT2B15), during infancy (UGT1A3, UGT1A4, and UGT1A9), to adolescence (UGT1A6 and UGT2B17). This study provides an extensive characterization of the postnatal ontogeny profiles of hepatic UGT enzymes that are instrumental for predicting drug disposition via in vitro-in vivo extrapolation algorithms and verifying pharmacokinetic predictions against in vivo observations via pediatric physiologically based pharmacokinetic modeling in pediatric patients.
Substances chimiques
Glucuronides
0
Isoenzymes
0
Glucuronosyltransferase
EC 2.4.1.17
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S42-S55Informations de copyright
© 2019, The American College of Clinical Pharmacology.
Références
Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013;45(6):1121-1132.
Owens IS, Basu NK, Banerjee R. UDP-Glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol. 2005;400:1-22.
Meech R, Mubarokah N, Shivasami A, et al. A novel function for UDP glycosyltransferase 8: galactosidation of bile acids. Mol Pharmacol. 2015;87(3):442-450.
Meech R, Rogers A, Zhuang L, Lewis BC, Miners JO, Mackenzie PI. Identification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymes. J Biol Chem. 2012;287(29):24122-24130.
Badée J, Fowler S, de Wildt SN, Collier AC, Schmidt S, Parrott N. The ontogeny of UDP-glucuronosyltransferase enzymes, recommendations for future profiling studies and application through physiologically based pharmacokinetic modelling. Clin Pharmacokinet. 2019;58(2):189-211.
Engtrakul JJ, Foti RS, Strelevitz TJ, Fisher MB. Altered AZT (3′-azido-3′-deoxythymidine) glucuronidation kinetics in liver microsomes as an explanation for underprediction of in vivo clearance: comparison to hepatocytes and effect of incubation environment. Drug Metab Dispos. 2005;33(11):1621-1627.
Soars MG, Ring BJ, Wrighton SA. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos. 2003;31(6):762-767.
Rowland A. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine - valproic acid interaction. Drug Metab Dispos. 2006;34(6):1055-1062.
Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35(9):1657-1663.
Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259-267.
Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21(3):291-301.
Yellepeddi V, Rower J, Liu X, Kumar S, Rashid J, Sherwin CMT. State-of-the-art review on physiologically based pharmacokinetic modeling in pediatric drug development. Clin Pharmacokinet. 2019;58(1):1-13.
Kapraun DF, Wambaugh JF, Setzer RW, Judson RS. Empirical models for anatomical and physiological changes in a human mother and fetus during pregnancy and gestation. Spradley FT, ed. PLoS One. 2019;14(5):e0215906.
Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation. Vol 44.; 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf.
Miyagi SJ, Collier AC. The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos. 2011;39(5):912-919.
Coughtrie MW, Burchell B, Leakey JE, Hume R. The inadequacy of perinatal glucuronidation: immunoblot analysis of the developmental expression of individual UDP-glucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol Pharmacol. 1988;34(6):729-735.
Miyagi SJ, Milne AM, Coughtrie MWH, Collier AC. Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. Drug Metab Dispos. 2012;40(7):1321-1327.
Neumann E, Mehboob H, Ramírez J, Mirkov S, Zhang M, Liu W. Age-dependent hepatic UDP-glucuronosyltransferase gene expression and activity in children. Front Pharmacol. 2016;7:437.
Zaya MJ, Hines RN, Stevens JC. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab Dispos. 2006;34(12):2097-2101.
Edginton A, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006;45(10):1013-1034.
Bhatt DK, Basit A, Zhang H, et al. Hepatic abundance and activity of androgen- and drug-metabolizing enzyme UGT2B17 are associated with genotype, age, and sex. Drug Metab Dispos. 2018;46(6):888-896.
Bhatt DK, Mehrotra A, Gaedigk A, et al. Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver. Clin Pharmacol Ther. 2019;105(1):131-141.
Divakaran K, Hines RN, McCarver DG. Human hepatic UGT2B15 developmental expression. Toxicol Sci. 2014;141(1):292-299.
Badée J, Qiu N, Parrott N, Collier AC, Schmidt S, Fowler S. Optimization of experimental conditions of automated glucuronidation assays in human liver microsomes using a cocktail approach and ultra-high performance liquid chromatography-tandem mass spectrometry. Drug Metab Dispos. 2019;47(2):124-134.
Concept Paper on the Need for Revision of the Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate. 2019. https://www.ema.europa.eu/en/documents/scientific-guideline/adopted-concept-paper-need-revision-guideline-investigation-medicinal-products-term-preterm-neonate_en.pdf.
Pacifici GM, Säwe J, Kager L, Rane A. Morphine glucuronidation in human fetal and adult liver. Eur J Clin Pharmacol. 1982;22(6):553-558.
Nie Y-L, He H, Li J-F, et al. Hepatic expression of transcription factors affecting developmental regulation of UGT1A1 in the Han Chinese population. Eur J Clin Pharmacol. 2017;73(1):29-37.
Leakey JE, Hume R, Burchell B. Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem J. 1987;243(3):859-861.
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet. 1999;36(6):439-452.
Miyagi SJ, Collier AC. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab Dispos. 2007;35(9):1587-1592.
Zhang Q, Cao YF, Ran RX, et al. Strong Specific Inhibition of UDP-glucuronosyltransferase 2B7 by Atractylenolide i and III. Phyther Res.. 2016;30(1):25-30.
Stachel N, Skopp G. [In vitro characterization of glucuronosyl- and sulfotransferases involved in the conjugation of ethanol]. Arch Kriminol. 2015;235(1-2):29-42.
Tanner J-A, Chenoweth MJ, Tyndale RF. Pharmacogenetics of nicotine and associated smoking behaviors. In: Current Topics in Behavioral Neurosciences. 2015;37-86.
Murphy SE, von Weymarn LB, Parenteau M, et al. Influence of UGT2B10 genotype on urinary excretion of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol- N- glucuronide by African American smokers. Chem Res Toxicol. 2018;31(3):168-175.
Chen A, Zhou X, Cheng Y, Tang S, Liu M, Wang X. Design and optimization of the cocktail assay for rapid assessment of the activity of UGT enzymes in human and rat liver microsomes. Toxicol Lett. 2018;295:379-389.
Ishii Y, Iida N, Miyauchi Y, Mackenzie PI, Yamada H. Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols. Biol Pharm Bull. 2012;35(10):1811-1817.
Hu DG, Mackenzie PI, McKinnon RA, Meech R. Genetic polymorphisms of human UDP-glucuronosyltransferase (UGT) genes and cancer risk. Drug Metab Rev. 2016;48(1):47-69.
Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in caucasians. Pharmacogenomics J. 2014;14(2):120-129.
Fowler S, Kletzl H, Finel M, et al. A UGT2B10 splicing polymorphism common in African populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352(2):358-367.
Benedetti MS, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today. 2007;12(15-16):599-610.
Grimstein M, Yang Y, Zhang X, et al. Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. food and drug administration's office of clinical pharmacology. J Pharm Sci. 2019;108(1):21-25.